Tetraphase Pharmaceuticals, Inc.
TTPH
TTPH was delisted on the 28th of July, 2020.
66 hedge funds and large institutions have $8.23M invested in Tetraphase Pharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 13 increasing their positions, 23 reducing their positions, and 24 closing their positions.
15% less funds holding
Funds holding: 78 → 66 (-12)
42% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 24
43% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 23
71% less capital invested
Capital invested by funds: $28.1M → $8.23M (-$19.9M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $10K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$481K |
| 2 |
Renaissance Technologies
New York
|
+$355K |
| 3 |
Jane Street
New York
|
+$234K |
| 4 |
Goldman Sachs
New York
|
+$233K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$221K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.27M |
| 2 |
State Street
Boston,
Massachusetts
|
-$960K |
| 3 |
Man Group
London,
United Kingdom
|
-$705K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$396K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$207K |
TTPH Hedge Fund Activity: Q2 2019 in Review
66 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q2 2019, worth a combined $8.23M — down 71% from $28.1M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of TTPH and 14 opened new positions — a net loss of 10 holders — while 23 trimmed existing stakes and 13 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $481K. The largest seller was BlackRock, cutting an estimated $2.27M.
- 66 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q2 2019, down from 78 in Q1 2019.
- Funds reported $8.23M of Tetraphase Pharmaceuticals, Inc. stock for Q2 2019, down 71% quarter-over-quarter.
- 14 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q2 2019 and 24 closed out, a net change of -10 holders.
- The largest Tetraphase Pharmaceuticals, Inc. buyer in Q2 2019 was Millennium Management, an estimated $481K added.
- The largest Tetraphase Pharmaceuticals, Inc. seller in Q2 2019 was BlackRock, an estimated $2.27M sold.
Based on aggregated 13F filings for Q2 2019.